Doctors, researchers on quest for a cure News-Herald.com, OH - Nov 28, 2008 Moore survived her own bout with breast cancer in 2000 because of advanced treatments and clinical studies. The five-year survival rate for breast cancer...
2008 marks year of Capitol events Arizona Republic, AZ - The event, organized to raise money to fight breast cancer, preceded a three-day, 60-mile walk through the East Valley in November, also to fight breast...
22 federal suits filed over hormone replacement drugs West Virginia Record, WV - In the complaints, the plaintiffs say they face an increased risk of heart attacks, blood clots, cardiovascular disease and breast cancer after taking ...
Raised hopes for prostate cancer sufferers Times Online, UK - Bisphosphonates, Fosamax-type drugs used to treat osteoporosis and breast cancer, have also been shown to delay the spread of prostate cancer. ...
Nanomagnets tackle cancer Science News - Two US research groups recently reported success in developing high-performance iron-cobalt nanomagnets for cancer therapy. New studies by another group ...
Teacher Learns The ABC?s Of Balancing Cancer And Career North American Press Syndicate, NY - Diagnosed at age 50 with stage III breast cancer in November 1999 and four years later with stage IV metastatic colorectal cancer, Suzanne bravely faced a ...
Dietz helps others cope with cancer Framingham TAB, USA - By John Hilliard For breast cancer survivor Blanche Dietz, helping other women battle cancer is part of her way to give back. Cancer "really changes you ...
Hopkins community raises funds for cancer victim Maryville Daily Forum, MO - The news that her daughter was diagnosed with breast cancer was devastating; however, she said she feels confident that, with the treatment available she?ll ...
Media scan Indianapolis Star, United States - 52 minutes ago Fighting breast cancer was not a life-altering experience for Shelley Lewis. In Five Lessons I Didn't Learn From Breast Cancer (and One Big One I Did) (New ...
Reports: Christina Applegate has breast cancer The Associated Press - Aug 3, 2008 LOS ANGELES (AP) ? Actress Christina Applegate reportedly is undergoing treatment for breast cancer. Ame Van Iden, publicist for the 36-year-old actress, ...
The Nottingham prognostic index in primary breast cancer - MH Galea, RW Blamey, CE Elston, IO Ellis - Breast Cancer Research and Treatment, 1992 - Springer ... patients or a group with a close to 100% mortality from breastcancer (Figure 1 ... some
measurable, such as growth rate or response to hormone therapies, and some ...
Breast cancer survivors: Psychosocial concerns and quality of life - PA Ganz, A Coscarelli, C Fred, B Kahn, ML Polinsky … - Breast Cancer Research and Treatment, 1996 - Springer BreastCancer Research and Treatment 38: 183-199, 1996. ? 1996 Kluwer Academic
Publishers. ... Physical effects of breastcancer surgery and other treatments ...
An evaluation of the quality of life among long-term survivors of breast cancer - KH Dow, BR Ferrell, S Leigh, J Ly, P Gulasekaram - Breast Cancer Research and Treatment, 1996 - Springer ... QOL-CS), the Functional Assessment of CancerTherapy (FACT-G ... Six hundred
seventy-eight cancer survivors (56 ... 43% of respon- dents) were breastcancer survivors. ...
Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer - J Kinoshita, K Kitamura, A Kabashima, H Saeki, S … - Breast Cancer Research and Treatment, 2001 - Springer ... of breastcancer. The VEGF-C positive patients should be closely followed up after
surgical treatment as they may be candidates for adjuvant therapy. Page 6. ...
Source: Google Scholar
Breast Cancer Therapies
Article Date: 13 Dec 2006 - 0:00 PST
EDITOR'S PICK: T-beta-RIII joins the fight against breast cancer
Although the soluble factor TGF-beta has been shown to suppress the growth of tumor cells in the early stages of breast cancer, high levels of TGF-beta during the later stages of the disease are associated with a poor outcome. A study using human breast cancer samples and mice, which appears online in December in advance of publication in the January print issue of the Journal of Clinical Investigation, indicates that changes in expression of one component of the TGF-beta receptor, T-beta-RIII, might provide a mechanism for the distinct effects of TGF-beta at the different stages of breast cancer.
Gerard Blobe and colleagues from Duke University showed that expression of T-beta-RIII by human breast cancer samples markedly decreased or was lost with disease progression. Conversely, in a mouse model of breast cancer, tumor cells engineered to express high levels of T-beta-RIII were less able to invade the breast tissue and to metastasize to other organs than tumor cells not engineered to express this protein. Further analysis revealed that the mechanism behind these protective effects of T-beta-RIII was likely to be T-beta-RIII cleavage at the cell membrane, which releases soluble T-beta-RIII that blocks TGF-beta signaling. As low levels of T-beta-RIII were found to be associated with decreased recurrence-free survival of patients with breast cancer and loss of T-beta-RIII was found to begin before tumors became invasive, the authors suggest that analysis of T-beta-RIII levels might help clinicians decide how aggressively to treat their patients.
Article continues below and (thank you)
TITLE: The type III TGF-beta receptor suppresses breast cancer progression
AUTHOR CONTACT:
Gerard C. Blobe
Duke University Medical Center
ONCOLOGY: The protein RB could help clinicians decide what breast cancer therapy is best
One protein that is functionally defective in most human cancers, including a third of all breast cancers, is RB. A study using human breast cancer cells, which appears online in December in advance of publication in the January print issue of the Journal of Clinical Investigation, shows that the presence or absence of functional RB influences the efficacy of therapies for breast cancer.
Erik Knudsen and colleagues from the University of Cincinnati showed that decreasing the expression of RB in human breast cancer cells increased their ability to proliferate and their tumorigenic potential. The cells from many breast cancer patients express the receptor for the hormone estrogen, and antiestrogen drugs such as tamoxifen are used to limit the growth of cancer cells in these patients. In this study, decreasing the expression of RB in human breast cancer cells made the cells unresponsive to tamoxifen. By contrast, decreasing the expression of RB in human breast cancer cells increased the sensitivity of the cells to radiation and other anticancer drugs, both of which are treatments given to patients with breast cancer who fail to respond to antiestrogen drugs such as tamoxifen. Importantly, breast cancer cells from patients in whom disease recurred very rapidly after treatment with tamoxifen had characteristics of cells lacking functional RB. This study indicates that analysis of RB functionality might be useful for clinicians to determine the most effective therapy for their patients.
TITLE: The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer
AUTHOR CONTACT:
Erik S. Knudsen
University of Cincinnati
